EFG Asset Management North America Corp. Has $1.65 Million Holdings in Repligen Corporation $RGEN

Key Points

• EFG Asset Management North America Corp. reduced its stake in Repligen Corporation by 33.0%, holding 12,923 shares worth approximately $1.65 million as of the latest SEC filing.
• Repligen reported Q2 earnings of $0.37 EPS, falling short of analysts' estimates, but achieved a revenue of $182.37 million, exceeding expectations.
• Analysts have set target prices for Repligen stock, with the consensus target price at $169.55, indicating a strong outlook with eight analysts rating it a "Buy."

EFG Asset Management North America Corp. lowered its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 33.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,923 shares of the biotechnology company's stock after selling 6,374 shares during the quarter. EFG Asset Management North America Corp.'s holdings in Repligen were worth $1,646,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in RGEN. Raiffeisen Bank International AG purchased a new position in Repligen during the 4th quarter valued at about $29,000. Twin Tree Management LP acquired a new position in Repligen during the 1st quarter worth approximately $29,000. Signaturefd LLC lifted its position in shares of Repligen by 65.3% during the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after buying an additional 128 shares during the last quarter. Center for Financial Planning Inc. lifted its position in shares of Repligen by 110.3% during the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock worth $47,000 after buying an additional 193 shares during the last quarter. Finally, UMB Bank n.a. raised its position in Repligen by 99.4% in the 1st quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 332 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Price Performance

Shares of Repligen stock traded up $3.98 during trading on Friday, reaching $124.56. The company's stock had a trading volume of 1,043,994 shares, compared to its average volume of 674,243. The stock has a 50-day moving average price of $121.53 and a two-hundred day moving average price of $129.06. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52. The stock has a market capitalization of $7.01 billion, a P/E ratio of -498.22, a price-to-earnings-growth ratio of 2.29 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same quarter in the previous year, the firm posted $0.40 earnings per share. Repligen's quarterly revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, sell-side analysts anticipate that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Evercore ISI lowered their price objective on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Royal Bank Of Canada reissued an "outperform" rating and set a $205.00 price target on shares of Repligen in a report on Tuesday. HC Wainwright reiterated a "buy" rating and issued a $180.00 price target on shares of Repligen in a research report on Wednesday. Wells Fargo & Company lowered their target price on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 30th. Finally, Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $169.55.

Insiders Place Their Bets

In other news, Director Martin D. Madaus acquired 1,800 shares of the firm's stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $112.13 per share, with a total value of $201,834.00. Following the acquisition, the director directly owned 1,800 shares in the company, valued at $201,834. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 1.20% of the company's stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.